Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients

  • Harnicar S
  • Adel N
  • Jurcic J
  • 21


    Mendeley users who have this article in their library.
  • 22


    Citations of this article.


Vincristine is an important component in the treatment of acute lymphoblastic leukemia (ALL) and is now the backbone of therapy in the induction and consolidation phases of this disease. Proper dosing of vincristine is required to maximize disease control while avoiding toxicity. The gastrointestinal toxicity of vincristine such as decreased peristalsis can potentially be increased if the CYP 3A4 enzyme is inhibited. This interaction may become more prevalent with increasing use of CYP 3A4 inhibitors such as the azole antifungals. Since azoles are increasingly being used for prophylaxis and treatment of fungal infections in this patient population, an assessment of vincristine dosing and toxicity is the first step to constructing guidelines for the coadministration of these agents.

Author-supplied keywords

  • Antifungal
  • Azoles
  • CYP3A4
  • Leukemia
  • Vincristine

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Stephen Harnicar

  • Nelly Adel

  • Joseph Jurcic

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free